At 82 years old, and with a sprawling resume worthy of its own Wikipedia entry, Malcolm McDowell isn’t afraid to speak freely ...

The average dividend yield in the S&P 500 Index remains low at around 1.3%. As a result, many stocks have lower dividend ...

During a live event, Tian Zhang, MD, MHS, discussed options and recent trial data for treating metastatic hormone-sensitive ...

PD-1 inhibitors are projected to dominate future drug sales. Immuno-oncology therapies, particularly the PD-(L)1 class, have revolutionized cancer ca ...

Bristol Myers Squibb, Merck & Company, and GE Healthcare Technologies continue advancing the cancer care ecosystem through ...

What is MFN in pharma? President Trump’s executive order on drug pricing states that the United States should be treated as a ...

With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...

BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the second ...

New Jersey officials are eyeing several efforts, including a massive $500 million incentive program meant to entice more products to be "Made in NJ." ...

Bristol Myers Squibb (BMS) has announced that its CD19-directed CAR T cell therapy Breyanzi (lisocabtagene maraleucel) has ...

While London South East do their best to maintain the high quality of the information displayed on this site, we cannot ...

Merck was a detractor despite "solid" first-quarter results, as it "disappointed the market" with a more subdued outlook for the rest of the year as it trimmed earlier guidance amid a slowdown in ...